Genflow to Present at LLWC 2022

RNS Number : 1340J

Genflow Biosciences PLC

25 April 2022

 

PRESS RELEASE

25 April 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Genflow to Present at Longevity Leaders 4^th World Congress 2022

Genflow (LSE: GENF) is pleased to announce that Eric Leire, the Company's Chief Executive Officer, will present an overview of the Company's pre-clinical research into gene therapies to target the aging process at the forthcoming Longevity Leaders World Congress ("LLWC"), 26-27 April 2022.

Mr Leire's presentation at the prestigious LLWC event will focus on the potential of the Sirtuin-6 ("SIRT6") gene variant found in centenarians (people aged more than 100 years old) to boost the development of anti-aging therapies. The ability of SIRT6 to act on the rejuvenation of cells is a significant finding, indicative of the SIRT6 gene mutation's potential to not just halt the aging process, but to reverse it.

Genflow intends to promote healthy aging by delivering extra copies of SIRT6 into cells by using adeno-associated virus ("AAV") vectors as a safe and efficient gene delivery system.

Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age.  It isthe first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.

Title:	Could a Gene Variant Found in Centenarians Boost Efforts to Develop Anti-aging Therapies?
Day/Date:	Tuesday 26 April 2022
Presentation Time:	14:55 - 15:30 BST

For further information please contact:

Genflow Biosciences Plc
Dr Eric Leire Chief Executive	via Tancredi [phone]
Clear Capital Markets Ltd
Corporate Broker  Jonathan Critchley Keith Swann	[phone] [phone]
Tancredi Intelligent Communication Media Relations
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio	[phone] [phone] [phone] [e-mail]

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit  www.genflowbio.com

-Ends-

 

END

 

 

MSCIIMTTMTATTMT